Bandyopadhyay, A. S., Gast, C., Rivera, L., Sáez-Llorens, X., Oberste, M. S., Weldon, W. C., Modlin, J., Clemens, R., Clemens, S. A. C., & Jimeno, J. (2021). Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: A randomised open-label, multicentre, phase 3, non-inferiority trial. The Lancet Infectious Diseases, 21(4), 559–568.https://www.thelancet.com/action/showPdf?pii=S1473-3099%2820%2930555-7
Chacon, G. P., Estcourt, M. J., Totterdell, J., Campbell, D. E., Perrett, K. P., Marsh, J. A., ... & Snelling, T. L. (2020). OPTIMUM study protocol: an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule. BMJ open, 10(12), e042838.https://bmjopen.bmj.com/content/bmjopen/10/12/e042838.full.pdf
Chitkara, A. J., Ferrer, M. P., Forsyth, K., Guiso, N., Heininger, U., Hozbor, D. F., ... & von König, C. W. (2020). Pertussis vaccination in mixed markets: Recommendations from the Global Pertussis Initiative. International Journal of Infectious Diseases, 96, 482-488.https://doi.org/10.1016/j.ijid.2020.04.081
Choy, R. K., Bourgeois, A. L., Ockenhouse, C. F., Walker, R. I., Sheets, R. L., & Flores, J. (2022). Controlled human infection models to accelerate vaccine development. Clinical Microbiology Reviews, 35(3), e00008-21.
Dolhain, J., Janssens, W., Sohn, W. Y., Dindore, V., & Mukherjee, P. (2019). Integration of hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine within existing national recommendations following a birth dose of monovalent hepatitis B virus vaccine: results of a systematic review in the Asia Pacific region. Expert Review of Vaccines, 18(9), 921-933. https://doi.org/10.1080/14760584.2019.1646643
Donato, C., Cowley, D., & Kirkwood, C. (2016). 10 Rotavirus. Foodborne Viral Pathogens, 179.
Gregori, L. M. (n.d.). Troubles neuropsychiatriques associés aux vaccins.
Halperin, S. A., Tapiero, B., Diaz-Mitoma, F., Law, B. J., Hoffenbach, A., Zappacosta, P. S., Radley, D., McCarson, B. J., Martin, J. C., & Brackett, L. E. (2009). Safety and immunogenicity of a hexavalent diphtheria–tetanus–acellular pertussis–inactivated poliovirus–Haemophilus influenzae b conjugate–hepatitis B vaccine at 2, 3, 4, and 12–14 months of age. Vaccine, 27(19), 2540–2547. https://doi.org/10.1016/j.vaccine.2008.11.115
Hayman, B., & Pagliusi, S. (2020). Emerging vaccine manufacturers are innovating for the next decade. Vaccine: X, 5, 100066.
Heininger, U., The, D.-H., Sänger, R., Jacquet, J.-M., & Schuerman, L. (2007). Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: Safety, immunogenicity and persistence of antibody responses. Vaccine, 25(6), 1055–1063.https://doi.org/10.1016/j.vaccine.2006.09.060
Koen, A., Madhi, S., Lyabis, O., Vidor, E., Cowper, B., Marais, T., ... & Vigne, C. (2021). Immunogenicity and safety of a hexavalent pediatric vaccine in HIV-exposed infected and uninfected infants in Republic of South Africa. Human Vaccines & Immunotherapeutics, 17(6), 1770-1778.https://doi.org/10.1080/21645515.2020.1839289
Kumar, P., Hamana, A., Bird, C., Dotson, B., Saleh-Birdjandi, S., Volkin, D. B., & Joshi, S. B. (2024). Evaluating the Compatibility of Three Aluminum Salt-Adjuvanted Recombinant Protein Antigens (Trivalent NRRV) Combined with a Mock Trivalent Sabin-IPV Vaccine: Analytical and Formulation Challenges. Vaccines, 12(10), 1102.https://doi.org/10.3390/vaccines12101102
Kumar, P., Bird, C., Holland, D., Joshi, S. B., & Volkin, D. B. (2022). Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication. Human Vaccines & Immunotherapeutics, 18(7), 2154100.https://www.tandfonline.com/doi/abs/10.1080/21645515.2022.2154100%4010.1080/tfocoll.2022.0.issue-Vaccine-Logisticshttps://www.tandfonline.com/
le Dr Richard Moskowitz, M. (n.d.). Médecin depuis plus de 50 ans, il déclare: L’hystérie actuelle au sujet de la rougeole ne repose nullement sur la science!
Le vaccin contre l’hépatite, B. (n.d.). À lire AVANT de voter la loi sur l’extension de l’obligation vaccinale!!
Madhi, S. A., Mitha, I., Cutland, C., Groome, M., & Santos-Lima, E. (2011). Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. The Pediatric Infectious Disease Journal, 30(4), e68-e74.DOI: 10.1097/INF.0b013e31820b93d2
Madhi, S. A., López, P., Zambrano, B., Jordanov, E., B’Chir, S., Noriega, F., & Feroldi, E. (2019). Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Human vaccines & immunotherapeutics, 15(3), 658-668.https://doi.org/10.1080/21645515.2018.1546524
Madhi, S. A., Koen, A., Cutland, C., Groome, M., & Santos-Lima, E. (2013). Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15–18 months of age in healthy South African infants. The Pediatric Infectious Disease Journal, 32(8), 889-897.
Mahmoud, A. (2011). A global road map is needed for vaccine research, development, and deployment. Health Affairs, 30(6), 1034–1041.
Mallet, E., Belohradsky, B. H., Lagos, R., Gothefors, L., Camier, P., Carrière, J.-P., Kanra, G., Hoffenbach, A., Langue, J., & Undreiner, F. (2004). A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety. Vaccine, 22(11–12), 1343–1357.https://doi.org/10.1016/j.vaccine.2003.09.039
Mangarule, S., Prashanth, S., Kawade, A., Ravi, M., Padmavathi, I., Palkar, S., Tripathi, V., Singh, R., Maurya, M., & Mitra, M. (2022). Lot-to-lot consistency of a hexavalent DTwP-IPV-HB-PRP∼ T vaccine and non-inferiority to separate DTwP-HB-PRP∼ T and IPV antigen-matching vaccines at 6–8, 10–12, and 14–16 weeks of age co-administered with oral rotavirus vaccine in healthy infants in India: A multi-center, randomized, controlled study. Vaccine: X, 12, 100216. https://doi.org/10.1016/j.jvacx.2022.100216
Mangarule, S., Palkar, S., Mitra, M., Ravi, M. D., Singh, R., Moureau, A., ... & Noriega, F. (2022). Antibody persistence following administration of a hexavalent DTwP-IPV-HB-PRP∼ T vaccine versus separate DTwP-HB-PRP∼ T and IPV vaccines at 12–24 months of age and safety and immunogenicity of a booster dose of DTwP-IPV-HB-PRP∼ T in healthy infants in India. Vaccine: X, 11, 100190.https://doi.org/10.1016/j.jvacx.2022.100190
Mangarule, S., Palkar, S., Mitra, M., Ravi, M. D., Dubey, A. P., Moureau, A., ... & Noriega, F. (2022). Safety and immunogenicity of a hexavalent DTwP-IPV-HB-PRP∼ T vaccine versus separate DTwP-HB-PRP∼ T and IPV vaccines in healthy infants in India. Vaccine: X, 10, 100137.https://doi.org/10.1016/j.jvacx.2021.100137
Mohanty, L., Sharma, S., Behera, B., Panwar, S., Paliwal, C., Gupta, A., ... & Singh, A. (2018). A randomized, open label trial to evaluate and compare the immunogenicity and safety of a novel liquid hexavalent DTwP-Hib/Hep B-IPV (EasySix™) to licensed combination vaccines in healthy infants. Vaccine, 36(17), 2378-2384.https://doi.org/10.1016/j.vaccine.2017.09.029
Mojgani, N. (2014). Immunogenicity and Efficacy of Different Haemophilus influenzae type b Vaccines. Archives of Razi Institute, 69(2), 115–125. 10.7508/ari.2014.02.001
Nunes, M. C., & Madhi, S. A. (2013). Review of a new fully liquid, hexavalent vaccine: Hexaxim. Expert opinion on biological therapy, 13(4), 575–593. https://doi.org/10.1517/14712598.2013.774368 DOI: 10.1517/14712598.2013.774368
Orsi, A., Azzari, C., Bozzola, E., Chiamenti, G., Chirico, G., Esposito, S., Francia, F., Lopalco, P., Prato, R., Russo, R., Villani, A., & Franco, E. (2018). Hexavalent vaccines: characteristics of available products and practical considerations from a panel of Italian experts. Journal of preventive medicine and hygiene, 59(2), E107–E119. https://pmc.ncbi.nlm.nih.gov/articles/PMC6069402/pdf/jpmh-2018-02-e107.pdf
Ozgenç, M. (n.d.). TURQUIE: Plus de 10.000 familles rejettent les vaccinations pour leurs enfants.
Patterson, J., Kagina, B. M., Gold, M., Hussey, G. D., & Muloiwa, R. (2017). Adverse events following primary and secondary immunisation with whole-cell pertussis: a systematic review protocol. BMJ open, 7(1), e012945.https://bmjopen.bmj.com/content/bmjopen/7/1/e012945.full.pdf
Ray, S., & Pemde, H. K. (2020). DIPHTHERIA, PERTUSSIS, TETANUS VACCINES. Indian Journal of Practical Pediatrics, 22(4), 367.https://iapindia.org/pdf/ijpp/Vol-22-No-4-VACCINOLOGY-I.pdf#page=7
Sanchez, L., Rungmaitree, S., Kosalaraksa, P., Jantarabenjakul, W., Leclercq, J., Yaiprayoon, Y., Midde, V. J., Varghese, K., Mangarule, S., & Noriega, F. (2023). Immunogenicity and Safety of a Hexavalent DTwP-IPV-HB-PRP~ T Vaccine Versus Separate DTwP-HB-PRP~ T, bOPV, and IPV Vaccines Administered at 2, 4, 6 Months of Age Concomitantly With Rotavirus and Pneumococcal Conjugate Vaccines in Healthy Infants in Thailand. The Pediatric Infectious Disease Journal, 42(8), 711–718. DOI: 10.1097/INF.0000000000003975
Sawant, N. (2021). Developability Assessments and Analytical Characterization of Recombinant Protein Antigens Formulated as Low-Cost, Multi-Dose, Aluminum-Adjuvanted Vaccines. University of Kansas. https://www.proquest.com/docview
Sharma, H., Lalwani, S., Parekh, S., Pujari, P., Shewale, S., Palkar, S., Hanumante, N., Gokhale, S., Ks, J., & Kumar, R. (2022). A phase I, open label, clinical study to assess the safety and immunogenicity of indigenously developed liquid (DTwP-HepB-IPV-Hib) hexavalent combination vaccine in healthy toddlers aged 16–24 months. Human Vaccines & Immunotherapeutics, 18(6), 2146435.https://doi.org/10.1080/21645515.2022.2146435
Vashishtha, V. M. (2018). Immunogenicity and safety of a novel liquid hexavalent DTwP-Hib/Hep B-IPV vaccine to licensed combination vaccines in healthy infants. Indian Pediatr, 55, 444.https://www.indianpediatrics.net/may2018/may-444.htm
World Health Organization. (2022). Bacterial vaccines in clinical and preclinical development 2021: An overview and analysis.https://books.google.co.za/books
Zepp, F., Knuf, M., Heininger, U., Jahn, K., Collard, A., Habermehl, P., Schuerman, L., & Sänger, R. (2004). Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. Vaccine, 22(17–18), 2226–2233.https://doi.org/10.1016/j.vaccine.2003.11.044